Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction

American Journal of Respiratory Cell and Molecular Biology

Volumn 56, Issue 4, 2017, Pages 497-505

  Meng, Qingqing ^a,b   Lai, Yen Chun ^a,c   Kelly, Neil J ^c   Bueno, Marta ^a,c   Baust, Jeffrey J ^a   Bachman, Timothy N ^a   Goncharov, Dmitry ^a   Vanderpool, Rebecca R ^a   Radder, Josiah E ^c   Hu, Jian ^a   Goncharova, Elena ^a,c   Morris, Alison M ^c   Mora, Ana L ^a,c   Shapiro, Steven D ^c   Gladwin, Mark T ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Tsinghua University   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AKR J; Group 2 pulmonary hypertension; Metabolic syndrome; Pulmonary hypertension; Pulmonary hypertension heart failure with preserved ejection fraction

Indexed keywords

HEMOGLOBIN A1C;

AKR MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE INTOLERANCE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID DIET; MALE; METABOLIC SYNDROME X; MOUSE; MOUSE MODEL; MOUSE STRAIN; NON SHILTJ MOUSE; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; REPRODUCIBILITY; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; WSB EIJ MOUSE; ANIMAL; BLOOD PRESSURE; COMPLICATION; DIASTOLE; DISEASE COURSE; DISEASE MODEL; HEART FAILURE; HEART STROKE VOLUME; PATHOLOGY; PATHOPHYSIOLOGY; SYSTOLE;

ANIMALS; BLOOD PRESSURE; DIASTOLE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART FAILURE; HYPERTENSION, PULMONARY; METABOLIC SYNDROME X; MICE; MICE, INBRED AKR; REPRODUCIBILITY OF RESULTS; STROKE VOLUME; SYSTOLE;

EID: 85017352361     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2016-0177OC     Document Type: Article

References (32)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 suppl):S43-S54.
2. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
3. Damy T, Goode KM, Kallvikbacka-Bennett A, Lewinter C, Hobkirk J, Nikitin NP, Dubois-RandéJL, Hittinger L, Clark AL, Cleland JG. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J 2010;31:2280-2290.
4. Delgado JF, Conde E, Sánchez V, López-Ŕios F, Gómez-Sánchez MA, Escribano P, Sotelo T, Gómez de la Cámara A, Cortina J, de la Calzada CS. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005;7: 1011-1016.
5. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010; 106:284-286.
6. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011;4:257-265.
7. Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J, Kalman J, Phillips RA, Steingart R, Brown EJ Jr, et al.; New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004;43: 1432-1438.
8. Gerges M, Gerges C, Pistritto AM, Lang MB, Trip P, Jakowitsch J, Binder T, Lang IM. Pulmonary hypertension in heart failure: epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med 2015; 192:1234-1246.
9. Vanderpool RR, Gladwin MT, Simon MA. Hemodynamic markers of pulmonary vascular disease in pulmonary hypertension due to left heart disease [abstract]. J Heart Lung Transplant 2015;34: S118.
10. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119: e21-e181.
11. Circulation 119:480-486
12. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2013;10: 401-410.
13. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002;105: 1663-1668.
14. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol 2009;53: 1119-1126.
15. Abramson SV, Burke JF, Kelly JJ Jr, Kitchen JG III, Dougherty MJ, Yih DF, McGeehin FC III, Shuck JW, Phiambolis TP. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992;116: 888-895.
16. Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail 2014;7:367-377.
17. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest 2007;131:94-100.
18. Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN, Zhao DX, Byrne DW. Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009;136: 31-36.
19. Lai YC, Tabima DM, Dube JJ, Hughan KS, Vanderpool RR, Goncharov DA, St Croix CM, Garcia-Ocaña A, Goncharova EA, Tofovic SP, et al. Sirt3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation 2016;133:717-731.
20. Kelly N, Fitch A, Michael H, Ghedin E, Tipton L, Lucht L, Gladwin MT, Shapiro SD, Morris AM. Susceptibility to high-fat diet-induced pulmonary hypertension is associated with reduced gi alphadiversity and altered species composition in mice [abstract]. Am J Respir Crit Care Med 2015;191:A3961.
21. Kelly N, Radder J, Baust J, Burton C, Agostini B, Wood J, Gregory A, Leme A, Shapiro SD. Genome-wide association study with interactome-based scoring identifies dok4 and ppp2ca as novel candidate genes in high-fat diet-induced pulmonary hypertension [abstract]. Am J Respir Crit Care Med 2016;193: A2219.
22. Meng Q, Bueno M, Kelly N, Lai YC, Mora AL, Gladwin MT. Evaluation of the therapeutic effects of nitrite and metformin in a mouse model of pulmonary hypertension associated with heart failure and preserved ejection fraction [abstract]. Am J Respir Crit Care Med 2016;193: A3888.
23. Kelly NJ, Radder JE, Baust JJ, Burton CL, Lai YC, Potoka KC, Agostini BA, Wood JP, Bachman TN, Vanderpool RR, et al. Mouse Genome-Wide Association Study of preclinical Group II pulmonary hypertension identifies epidermal growth factor receptor. Am J Respir Cell Mol Biol 2017;56: 488-496.
24. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gactivation. Circulation 2007;115:1275-1284.
25. Kelley EE, Baust J, Bonacci G, Golin-Bisello F, Devlin JE, St Croix CM, Watkins SC, Gor S, Cantu-Medellin N, Weidert ER, et al. Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity. Cardiovasc Res 2014;101:352-363.
26. Alexander J, Chang GQ, Dourmashkin JT, Leibowitz SF. Distinct phenotypes of obesity-prone AKR/J, DBA2J and C57BL/6J mice compared to control strains. Int J Obes 2006; 30:50-59.
27. Ussar S, Fujisaka S, Kahn CR. Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. Mol Metab 2016;5:795-803.
28. Ishimori N, Li R, Kelmenson PM, Korstanje R, Walsh KA, Churchill GA, Forsman-Semb K, Paigen B. Quantitative trait loci that determine plasma lipids and obesity in C57BL/6J and 129S1/SvImJ inbred mice. J Lipid Res 2004;45:1624-1632.
29. Rossmeisl M, Rim JS, Koza RA, Kozak LP. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 2003;52:1958-1966.
30. Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin MA, Morio B, Vidal H, Rieusset J. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest 2008;118:789-800.
31. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5:601-604.
32. O'Brien PD, Sakowski SA, Feldman EL. Mouse models of diabetic neuropathy. ILAR J 2014;54:259-272.